Trials / Active Not Recruiting
Active Not RecruitingNCT02988960
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 163 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-927 | Intravenous |
| DRUG | ABBV-927 | Intratumoral |
| DRUG | ABBV-181 | Intravenous |
Timeline
- Start date
- 2017-02-22
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2016-12-12
- Last updated
- 2026-01-09
Locations
22 sites across 7 countries: United States, Australia, Canada, France, Japan, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02988960. Inclusion in this directory is not an endorsement.